medigraphic.com
Órgano Oficial de el Colegio Mexicano de Urología

2003, Number 4

<< Back Next >>

Bol Col Mex Urol 2003; 18 (4)

Risk factors associated to biochemical recurrence after radical prostatectomy in localized prostate cancer

Wingartz PHF, Velázquez MIO, Cedillo LU, López SV, Serrano BEA

Language: Spanish
References: 30
Page: 135-140
PDF size: 100.27 Kb.


ABSTRACT

During the past 12 years, routine use of serum prostate-specific antigen (PSA) has resulted in a significant increase in the proportion of patients initially diagnosed with clinically localized disease. The study comprised a sample of 53 patients with localized prostate cancer who underwent radical prostatectomy and bilateral pelvic lymphadenectomy between 1994 and 2001. Predictive risk factors for biochemical recurrence in patients with localized prostate cancer after radical prostatectomy were analyzed. With p < 0.05 used for testing significance. The term of biochemical recurrence was determinated when two or more serum prostate-specific antigen separate measurements reveal a greater level detection (0.5 ng/mL or more) at any time after about 4 weeks postoperatively. From 53 patients, 16 had biochemical recurrence (30%) (group I) and 37 were free of relapse (70%) (group II). In group I, 7 patients (44%) had a digital rectal examination (DRE) suspicious (p = 0.749), 14 patients (88%) had PSA > 10 ng/mL (p = 0.0239), 9 patients (56%) with pathologic T stage (pT3) (p = 0.696) and 9 patients (56%) a Gleason score > 7 (p = 0.779). In group II, 20 patients (54%) had a DRE suspicious (p = 0.542), 3 patients (8%) had PSA > 10 ng/mL (p = 0.0142), 6 patients (16%) with pathologic T stage (pT3) (p = 0.0412) and 8 patients (22%) a Gleason score > 7 (p = 0.0449). Both groups were compared, the preoperative prostate-specific antigen (PSA) > 10 ng/mL had a significant difference (p = 0.0235) and the preoperative prostate-specific antigen (PSA) < 10 ng/mL had a significant difference too (p = 0.0337). The pathologic T stage (pT3) between both groups had significant difference (p = 0.0494). At present, study the predictive risk factors for biochemical recurrence in patients with localized prostate cancer after radical prostatectomy were the preoperative serum prostate-specific antigen > 10 ng/mL and a pathologic T stage (pT3).


REFERENCES

  1. Pound CR, Laufer M, Carducci M, Eisenberger M. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000; 55(3): 309-315.

  2. Brawer MK, Stamey T, Jackson F. Perspectives on prostate cancer diagnosis and treatment: A roundtable. Urology 2001; 58: 135-140.

  3. Litwin MS, Pasta DJ, Stoddard ML. Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries 1991 to 1993. J Urol 1998; 160: 445-448.

  4. Hu JC, Gold KF, Pashos CL. Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol 2003; 169: 1443-1448.

  5. Gee WF, Holtgrewe HL, Blute ML. 1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol 1998; 160: 1804-1807.

  6. Stephenson RA. Population-based prostate cancer trends in the PSA era: Data from the Surveillance, Epidemiology, and End Results (SEER) Program 1998. J Urol 2000; 197: 19-23.

  7. Montie JE. Follow up after radical prostatectomy or radiation therapy for prostate cancer. J Urol 2000; 192: 673-676.

  8. Jhaveri FM, Zippe CD, Klein EA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-years results. Urology 1999; 58: 884-890.

  9. Pound CR, Partin AW, Epstein J. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406.

  10. Blute ML. Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000; 164: 1591-1595.

  11. Lieskovsky G, Bochner BH, Skinner EC. Evaluation of 20-year experience with radical retropubic prostatectomy for adenocarcinoma of the prostate (abstract). J Urol 1999; 161: A329.

  12. Salomon CG, Flisak ME, Olson MC. Radical prostatectomy: transrectal sonographic evaluation to assess for local recurrence. J Urol 1998; 149: 713-719.

  13. Kramer S, Gorich J, Gottfried HW. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. J Urol 1997; 170: 995-999.

  14. Kahn D, Williams RD, Manyak MJ. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998; 159: 2041-2046.

  15. Ornstein DK, Colberg JW, Virgo KS. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 1998; 52: 1047-1054.

  16. Soloway MS, Neulander EZ. Failure after radical prostatectomy. Urology 2003; 61: 30-36.

  17. Epstein JI, Partin AW, Sauvageot J. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow up. Am J Surg Pathol 1996; 20: 286-292.

  18. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - what have we learned and where are we going. J Urol 1999; 162: 293-299.

  19. Sobin LH, Wittekind. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. Wiley-Liss, New York, 2003.

  20. Pound CR, Partin AW, Eisenberger M. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.

  21. Partin AW, Leslie AM, Lamm DM, Walsh PC. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-848.

  22. Obek C, Sadek S, Lai S. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology 1999; 54: 682-688.

  23. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer intermediate-term results. J Urol 1998; 160: 2428-2434.

  24. Kupelian PA, Katcher J, Levin HS. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. J Urol 1997; 137: 1043-1052.

  25. Partin AW, Pearson JD, Landis PK. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43: 649-654.

  26. Scattoni V, Montorsi F, Picchio M, Roscigno M. Diagnosis of local recurrence after radical prostatectomy. BJU 2004; 93(5): 680-688.

  27. Zincke H, Oesterling JE, Blute ML. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-1857.

  28. Ohori M, Wheeler TM, Kattan MW. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818-1824.

  29. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-923.

  30. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 15: 1358-1368.




2020     |     www.medigraphic.com